Adnan Jehangir Malik

Dr. Adnan Jehangir Malik

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MOHAMMAD MUZAFFAR MIRMOHAMMAD MUZAFFAR MIR
MOHAMMAD MUZAFFAR MIR
Mohammed JeelaniMohammed Jeelani
Mohammed Jeelani
MAMuffarah Hamid Alharthi
Muffarah Hamid Alharthi
SRSyeda Fatima Rizvi
Syeda Fatima Rizvi
SSShahzada Khalid Sohail
Shahzada Khalid Sohail
RMRashid Mir
Rashid Mir
Insulin resistance (IR) is a significant factor in the development and progression of metabolic-related diseases like dyslipidemia, T2DM, hypertension, nonalcoholic fatty liver disease, cardiovascular and cerebrovascular disorders, and cancer. The pathogenesis of IR depends on multiple factors, including age, genetic predisposition, obesity, oxidative stress, among others. Abnormalities in the insulin-signaling cascade lead to IR in the host, including insulin receptor abnormalities, internal environment disturbances, and metabolic alterations in the muscle, liver, and cellular organelles. The complex and multifaceted characteristics of insulin signaling and insulin resistance envisage their thorough and comprehensive understanding at the cellular and molecular level. Therapeutic strategies for IR include exercise, dietary interventions, and pharmacotherapy. However, there are still gaps to be addressed, and more precise biomarkers for associated chronic diseases and lifestyle interventions are needed. Understanding these pathways is essential for developing effective treatments for IR, reducing healthcare costs, and improving quality of patient life.

24 February 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MOHAMMAD MUZAFFAR MIRMOHAMMAD MUZAFFAR MIR
MOHAMMAD MUZAFFAR MIR
Mohammed JeelaniMohammed Jeelani
Mohammed Jeelani
MAMuffarah Hamid Alharthi
Muffarah Hamid Alharthi
SRSyeda Fatima Rizvi
Syeda Fatima Rizvi
SSShahzada Khalid Sohail
Shahzada Khalid Sohail
RMRashid Mir
Rashid Mir
Insulin resistance (IR) is a significant factor in the development and progression of metabolic-related diseases like dyslipidemia, T2DM, hypertension, nonalcoholic fatty liver disease, cardiovascular and cerebrovascular disorders and cancer. The pathogenesis of IR depends on multiple factors including age, genetic predisposition, obesity, oxidative stress and other factors. Abnormalities in the insulin signaling cascade lead to IR in the host, including insulin receptor abnormalities, internal environment disturbances, and metabolic alterations in the muscle, liver and cellular organelles. The complex and multifaceted characteristics of insulin signaling and insulin resistance envisage its thorough and comprehensive understanding at the cellular and molecular level. Therapeutic strategies for IR include exercise, dietary interventions and pharmacotherapy. However, there are still gaps to be addressed, and more precise biomarkers for associated chronic diseases and lifestyle interventions are needed. Understanding these pathways is essential for developing effective treatments for IR, reducing healthcare costs and improving quality of patient life.

24 February 2026 in International Medical Education
Verified
Journal Article
Open access
PDF file
MOHAMMAD MUZAFFAR MIRMOHAMMAD MUZAFFAR MIR
MOHAMMAD MUZAFFAR MIR
MAMuffarah Hamid Alharthi
Muffarah Hamid Alharthi
JAJaber A Alfaifi
Jaber A Alfaifi
SSShahzada Khalid Sohail
Shahzada Khalid Sohail
SMSaba Muzaffar Mir
Saba Muzaffar Mir
AMAdnan Jehangir Malik
Adnan Jehangir Malik
Artificial intelligence (AI), particularly generative AI, is rapidly reshaping medical education worldwide. While AI-enabled tools offer significant opportunities for personalized learning, feedback automation, and clinical reasoning support, they simultaneously challenge foundational principles of assessment integrity and professional conduct. Traditional assessment models—largely predicated on individual authorship, knowledge recall, and observable performance—are increasingly strained by AI systems capable of generating sophisticated responses, analyses, and clinical narratives. This disruption has prompted urgent reconsideration of what constitutes academic honesty, valid assessment, and professional identity formation in contemporary medical training. This article critically examines the intersection of AI, assessment integrity, and professionalism in medical education from a global perspective, with particular attention to the experiences and emerging lessons from the Gulf Cooperation Council (GCC). The GCC provides a distinctive context characterized by rapid digital transformation, centralized accreditation and licensing systems, high-stakes assessments, and strong sociocultural norms governing professional behavior. These features make the region an instructive case for understanding how medical education systems respond to AI-driven challenges at scale. The article employs a critical narrative and conceptual framework, positioning generative AI as a normative disruptor that necessitates a reevaluation of assessment validity, ethical accountability, and the construction of professional identity. Utilizing worldwide scholarship, policy frameworks, and regional experiences, the analysis underscores that misalignment between assessment design and professional expectations jeopardizes trust, fairness, and public confidence. The essay advocates for a transition from reactive restriction to the principled integration of AI, highlighting the need for assessment redesign, AI literacy matched with professionalism, teacher development, and cohesive governance. These insights are intended to guide educators, institutions, and regulators in maintaining professional standards inside AI-enhanced medical education systems.

27 November 2025 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
SAShahid Aziz
Shahid Aziz
JWJaved Iqbal Wani
Javed Iqbal Wani
SASaif Aboud M. Alqahtani
Saif Aboud M. Alqahtani
HDHumayoun Khan Durrani
Humayoun Khan Durrani
AMAdnan Jehangir Malik
Adnan Jehangir Malik
NANiemat Mohammed Tahir Ali
Niemat Mohammed Tahir Ali
Insulin resistance (IR) plays a significant role in the development of cardiovascular disease (CVD), even in non-diabetic individuals, with a 46% higher li

1 January 2025
Verified
Journal Article
Open access
PDF file
AMAdnan Jehangir Malik
Adnan Jehangir Malik
FMFarhana ayub Malik
Farhana ayub Malik
Objective: The primary aim of this study is to evaluate the efficacy and safety of emerging disease-modifying therapies in Alzheimer's disease, comparing their effects with traditional symptomatic treatments. Methods: This randomized, double-blind, placebo-controlled trial enrolled 200 participants diagnosed with mild to moderate Alzheimer's disease. Participants were randomly assigned to one of four groups: (1) symptomatic treatment with Donepezil, (2) symptomatic treatment with Memantine, (3) disease-modifying therapy with a monoclonal anti-amyloid antibody (e.g., Aducanumab), or (4) placebo. The primary endpoint was the change in cognitive function, assessed using the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) over 12 months. Secondary outcomes included changes in functional status (Activities of Daily Living scale), quality of life (QoL-AD), and adverse events. Results: Cognitive Function: The disease-modifying therapy group showed a statistically significant reduction in ADAS-Cog scores compared to both symptomatic treatment and placebo groups (p < 0.05), indicating potential disease-modifying effects. Functional Status and Quality of Life: No significant differences were observed between symptomatic treatments and the placebo in improving functional status. However, patients in the disease-modifying group demonstrated improvements in the QoL-AD scores (p < 0.05). Adverse Events: Both symptomatic treatments and disease-modifying therapies were well tolerated. The most common adverse events in the disease-modifying therapy group were mild infusion-related reactions and headaches, which resolved over time. Conclusions: This study suggests that disease-modifying therapies targeting amyloid plaques may offer a promising approach to slowing cognitive decline in Alzheimer's disease. Although symptomatic treatments remain the mainstay of current care, disease-modifying drugs could transform the therapeutic landscape for AD, offering hope for halting or slowing disease progression. Larger, long-term studies are needed to confirm the durability of these effects and their potential role in clinical practice.

24 August 2026 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
PDF file
SHSajid Hussain Altaf Hussain
Sajid Hussain Altaf Hussain
HSHowaida Shaker Saati
Howaida Shaker Saati
MAMarya Ahsan
Marya Ahsan
RORazan Orfali
Razan Orfali
FMFarhana ayub Malik
Farhana ayub Malik
AMAdnan Jehangir Malik
Adnan Jehangir Malik